This is a single-arm pilot study assessing the feasibility and acceptability of the Companion for CAR-T (CC) web app among patients receiving commercially available CAR-T therapies.~Primary Objectives:~I. To evaluate the feasibility of the CC web app. II. To evaluate the acceptability of the CC web app to patients.~Secondary Objectives:~I. To quantify the incidence of fevers being reported via the CC web app. II. To quantify the incidence of electronic Immune Effector Cell-Associated Encephalopathy (eICE) deficits being recorded via the CC web app.~Exploratory Objectives:~I. To explore patient perceptions regarding the CC web app. II. To explore usage patterns regarding the CC web app. III. To explore trends in patient-reported quality of life (QOL), values, and stressors over time during CAR-T therapy.~IV. To explore responses to abnormal findings reported or recorded using the CC web app~Participants will be given access to the web application from beginning at the day of study enrollment through Day +100 following CAR-T therapy.
The complex logistics and unique toxicities of chimeric antigen receptor T-cell (CAR-T) therapy require intensive patient education and careful monitoring. The Companion for CAR-T (CC) web app may be able to assist with patient education and preparation, communication between patients and their multidisciplinary teams, and home-based toxicity monitoring.